Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The development of simple, noninvasive markers of liver fibrosis is urgently needed for primary biliary cirrhosis (PBC). This study examined the ability of several serum biomarkers of cell death to estimate fibrosis and prognosis in PBC. A cohort of 130 patients with biopsy-proven PBC and 90 healthy subjects were enrolled. We assessed the utility of the M30 ELISA, which detects caspase-cleaved cytokeratin-18 (CK-18) fragments and is representative of apoptotic cell death, as well as the M65 and newly developed M65 Epideath (M65ED) ELISAs, which detect total CK-18 as indicators of overall cell death, in predicting clinically relevant fibrosis stage. All 3 cell death biomarkers were significantly higher in patients with PBC than in healthy controls and were significantly correlated with fibrosis stage. The areas under the receiver operating characteristic curve for the M65 and M65ED assays for differentiation among significant fibrosis, severe fibrosis, and cirrhosis were 0.66 and 0.76, 0.66 and 0.73, and 0.74 and 0.82, respectively. In multivariate analysis, high M65ED (hazard ratio 6.13; 95% confidence interval 1.18-31.69; P = 0.031) and severe fibrosis (hazard ratio 7.45; 95% confidence interval 1.82-30.51; P = 0.005) were independently associated with liver-related death, transplantation, or decompensation. High serum M65ED was also significantly associated with poor outcome in PBC (log-rank test; P = 0.001). Noninvasive cell death biomarkers appear to be clinically useful in predicting fibrosis in PBC. Moreover, the M65ED assay may represent a new surrogate marker of adverse disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Serum levels of wisteria floribunda agglutinin-positive mac-2 binding protein (WFA + -M2BP) and cytokeratin 18 have also shown prognostic ability in PBC, but validation is required [84,85].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey
Cadranel, J.-F., Rufat, P., & Degos, F. (2000) · Hepatology · doi:10.1053/jhep.2000.16602 · Cited by 993
(2015) · Diagnostic Imaging: Gastrointestinal · doi:10.1016/b978-0-323-37755-3.50202-6 · Cited by 811
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Feldstein, A. E., Wieckowska, A., Lopez, R. A., Liu, Y.-C., Zein, N. N., & McCullough, A. J. (2009) · Hepatology · doi:10.1002/hep.23050 · Cited by 712
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287 · cited 2×
“[5–7] Both apoptosis and necrosis have been proposed to be responsible for the development and progression of liver fibrosis.[4, 8] Various caspases are activated during apoptosis in PBC.”
BackgroundA Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)
Younossi, Z. M., Jarrar, M., Nugent, C., Randhawa, M., Afendy, M., Stepanova, M., Rafiq, N., Goodman, Z., Chandhoke, V., & Baranova, A. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9506-y · Cited by 277
Hirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Umemura, T., Zen, Y., Hamano, H., Kawa, S., Nakanuma, Y., & Kiyosawa, K. (2007) · Hepatology · doi:10.1002/hep.21700 · Cited by 251
Self-citationBantel, H., Lügering, A., Heidemann, J., Volkmann, X., Poremba, C., Strassburg, C. P., Manns, M. P., & Schulze-Osthoff, K. (2004) · Hepatology · doi:10.1002/hep.20411 · Cited by 242 · cited 2×
“Bantel et al.[9] have developed a novel ELISA based on the M30 antigen that selectively recognizes an exposed neoepitope after cleavage of the CK-18 caspase substrate.”
BackgroundMethodBiomarkers of liver cell death
Eguchi, A., Wree, A., & Feldstein, A. E. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.026 · Cited by 220 · cited 1×
“, necrosis).[6, 7] Hepatocyte death is the key trigger of liver disease progression, which is characterized by inflammation, and fibrosis.”
BackgroundOdin, J. A., Huebert, R. C., Casciola-Rosen, L., LaRusso, N. F., & Rosen, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200110716 · Cited by 220 · cited 1×
“Odin et al.[33] observed that PDC-E2 was neither cleaved by caspases nor concentrated into surface blebs in apoptotic cells.”
BackgroundJoka, D., Wahl, K., Moeller, S., Schlue, J., Vaske, B., Bahr, M. J., Manns, M. P., Schulze-Osthoff, K., & Bantel, H. (2012) · Hepatology · doi:10.1002/hep.24734 · Cited by 184 · cited 1×
“There exists another study in which all 3 cell death biomarkers were examined in non-alcoholic steatohepatitis.[20] The specificity of M30, M65, and M65ED was 61%, 67%, and 68%, respectively, to discriminate significant fibrosis and 71%, 78%, and 77%, respectively, to estimate progressed fibrosis/cirrhosis.”
BackgroundDiab, D. L., Yerian, L., Schauer, P., Kashyap, S. R., Lopez, R., Hazen, S. L., & Feldstein, A. E. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.07.016 · Cited by 168
Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis
Harada, K., Ozaki, S., Gershwin, M. E., & Nakanuma, Y. (1997) · Hepatology · doi:10.1002/hep.510260604 · Cited by 167
Bechmann, L. P., Jochum, C., Kocabayoglu, P., Sowa, J.-P., Kassalik, M., Gieseler, R. K., Saner, F., Paul, A., Trautwein, C., Gerken, G., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.029 · Cited by 162
Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis
Koga, H., Sakisaka, S., Ohishi, M., Sata, M., & Tanikawa, K. (1997) · Hepatology · doi:10.1002/hep.510250505 · Cited by 134 · cited 2×
“However, this may underscore the need to establish noninvasive fibrosis markers in PBC. Increased cholangiocyte apoptosis in the presence of activated cytotoxic T cells is evident in PBC,[30–32] in which autoantibodies are specific for a conformation-dependent epitope of the doi:10.1371/journal.pone.0131658.g003 PLOSO…”
BackgroundInfluentialUmemura, T., Joshita, S., Sekiguchi, T., Usami, Y., Shibata, S., Kimura, T., Komatsu, M., Matsumoto, A., Ota, M., & Tanaka, E. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.118 · Cited by 127
Self-citationAFFORD, S. C., AHMED-CHOUDHURY, J., RANDHAWA, S., RUSSELL, C., YOUSTER, J., CROSBY, H. A., ELIOPOULOS, A., HUBSCHER, S. G., YOUNG, L. S., & ADAMS, D. H. (2001) · The FASEB Journal · doi:10.1096/fj.01-0088com · Cited by 119
Caspase activation is associated with spontaneous recovery from acute liver failure
Volkmann, X., Anstaett, M., Hadem, J., Stiefel, P., Bahr, M. J., Lehner, F., Manns, M. P., Schulze-Osthoff, K., & Bantel, H. (2008) · Hepatology · doi:10.1002/hep.22237 · Cited by 107 · cited 4×
“[9] We also adopted the M65 and improved M65ED ELISAs (Pevia), which quantify both caspase-cleaved and uncleaved CK-18.[10] All assays were performed under blinded conditions.”
MethodInfluentialAccuracy of staging in primary biliary cirrhosis.
Garrido, M. C., & Hubscher, S. G. (1996) · Journal of Clinical Pathology · doi:10.1136/jcp.49.7.556 · Cited by 94 · cited 1×
“[2, 3] Moreover, there is considerable variation in the degree of fibrosis throughout the liver of PBC patients; in one study, fibrosis not detected in small needle biopsy specimens was regularly witnessed in hepatectomy samples obtained at transplantation, and only 36% of hepatectomy samples were concordant with the…”
BackgroundNoninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
Francque, S., Verrijken, A., Mertens, I. L., Hubens, G., Marck, E. V., Pelckmans, P. A., Michielsen, P. P., & Gaal, L. V. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.06.019 · Cited by 89
Tsutsui, M., Tanaka, N., Kawakubo, M., Sheena, Y., Horiuchi, A., Komatsu, M., Nagaya, T., Joshita, S., Umemura, T., Ichijo, T., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181bdefe2 · Cited by 83
Self-citationSerum Apoptosis Markers in Acute Liver Failure: A Pilot Study
Rutherford, A., Hynan, L. S., Borges, C. B. D. S., Forcione, D. G., Blackard, J. T., Lin, W., Gorman, A., Shaikh, O. S., Reuben, A., Harrison, E. M., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.08.007 · Cited by 76
Waidmann, O., Köberle, V., Bettinger, D., Trojan, J., Zeuzem, S., Schultheiß, M., Kronenberger, B., & Piiper, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.008 · Cited by 74 · cited 1×
“[34] Furthermore, lower serumM65 levels have been associated with longer overall survival in hepatocellular carcinoma.[35] Here, higher M65ED, but not M30, levels correlated with a poor outcome, implying that the assessment of necrotic hepatocyte death could be a suitable prognostic marker as well.”
BackgroundUmemura, T., Joshita, S., Ichijo, T., Yoshizawa, K., Katsuyama, Y., Tanaka, E., & Ota, M. (2012) · Hepatology · doi:10.1002/hep.24705 · Cited by 74
Self-citationMehal, W., & Imaeda, A. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255352 · Cited by 70 · cited 1×
“[5–7] Both apoptosis and necrosis have been proposed to be responsible for the development and progression of liver fibrosis.[4, 8] Various caspases are activated during apoptosis in PBC.”
BackgroundSeidel, N., Volkmann, X., Länger, F. P., Flemming, P., Manns, M. P., Schulze‐Osthoff, K., & Bantel, H. (2005) · Hepatology · doi:10.1002/hep.20747 · Cited by 69
Koehler, E., Swain, J., Sanderson, S., Krishnan, A., Watt, K., & Charlton, M. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02637.x · Cited by 60
Papatheodoridis, G., Hadziyannis, E. S., Tsochatzis, E. A., Chrysanthos, N. V., Georgiou, A., Kafiri, G., Manolakopoulos, S., TINIAKOS, D. G., Giannousis, I. P., Manesis, E. K., et al. (2007) · Gut · doi:10.1136/gut.2007.123943 · Cited by 47
Petris, L. D., Brandén, E., Herrmann, R., Sanchez, B. C., Koyi, H., Linderholm, B. K., Lewensohn, R., Linder, S., & Lehtiö, J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.08.006 · Cited by 44 · cited 1×
“Although the newly developed M65 Epideath (ED) ELISA also represents total cell death, it uses the M6 antibody for detection and M5 as the capture antibody, resulting in improved binding specificity and lower signals in healthy controls.[22] To date, reports have been scarce regarding CK18 fragments in PBC.”
MethodDenk, G., Omary, A., Reiter, F. P., Hohenester, S. D., Wimmer, R., Holdenrieder, S., & Rust, C. (2014) · Hepatology Research · doi:10.1111/hepr.12304 · Cited by 24
Li, X., Zhang, Y., Wu, K., & Fan, D. (2009) · Hepatology · doi:10.1002/hep.23433 · Cited by 9
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
“Serum levels of wisteria floribunda agglutinin-positive mac-2 binding protein (WFA-M2BP) and cytokeratin 18 have also shown prognostic ability in PBC, but validation is required [84,85].”
Cell death markers in patients with cirrhosis and acute decompensation
Macdonald, S., Andreola, F., Bachtiger, P., Amoros, A., Pavesi, M., Mookerjee, R., Zheng, Y. B., Gronbaek, H., Gerbes, A. L., Sola, E., et al. (2018) · Hepatology · doi:10.1002/hep.29581 · Cited by 99
“Markers of cell death, in particular, caspase-cleaved keratin 18 (cK18) and keratin 18 (K18), have been previously demonstrated to be clinically relevant in the diagnosis, assessment of disease severity, and prognosis of a wide range of acute and chronic liver diseases, including chronic and acute on chronic hepatitis…”
BackgroundHöfer, A., Jonigk, D. D., Hartleben, B., Verboom, M., Hallensleben, M., Manns, M. P., Jaeckel, E., & Taubert, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-70938-7 · Cited by 37
Alt, Y., Grimm, A., Schlegel, L., Grambihler, A., Kittner, J. M., Wiltink, J., Galle, P. R., Wörns, M., & Schattenberg, J. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151200 · Cited by 32
Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis
Chen, S., Wan, Q.-S., Wang, T., & Zhang, K.-H. (2020) · BioMed Research International · doi:10.1155/2020/7170457 · Cited by 30
“[44] detected M30, M65, and M65EpiDeath in 130 PBC patients and found that they were all significantly higher in PBC than in healthy controls and were significantly correlated with fibrosis stage; the mortality was significantly higher in patients with high M65EpiDeath levels (HR: 6.”
Background
Metadata
- Authors
- Sekiguchi, T., Umemura, T., Fujimori, N., Shibata, S., Ichikawa, Y., Kimura, T., Joshita, S., Komatsu, M., Matsumoto, A., Tanaka, E., & Ota, M.
- Affiliations
- Shinshu University (JP)
- Corresponding author
- Umemura, Takeji
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-25
- Volume
- 10
- Issue
- 6
- Pages
- e0131658
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4482393
- OpenAlex
- W828765355
- Cited by
- 27
- References
- 39
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 5 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (15H01803, 26460996)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, liver fibrosis, cell death biomarkers, cytokeratin 18, apoptosis, noninvasive fibrosis staging, prognosis, liver-related mortality, liver transplantation, hepatic decompensation
- MeSH terms
- Aged, Biopsy, Enzyme-Linked Immunosorbent Assay, Female, Humans, Japan, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Prognosis, ROC Curve, Biomarkers, Case-Control Studies, Treatment Outcome, Cell Death, Apoptosis, Kaplan-Meier Estimate, Keratin-18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.